Business Wire

On the International Day of Happiness, Finland Calls for International Business Cooperation to Solve Major Global Challenges Together

20.3.2025 01:15:00 CET | Business Wire | Press release

Share

Societal stability, high levels of equality and, among other things, political and civil freedom are frequently highlighted as the key factors contributing to Finland's status as the world’s happiest country in recent years, as reflected in the World Happiness Report. These are the building blocks of the trust and mutual respect that permeate Finnish society, enabling innovative international cooperation and providing an excellent launchpad for business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319812998/en/

Photo credits: Svante Gullichsen & Visit Finland

In Finnish society, there are many factors that underscore succeeding together: an education system that emphasizes teamwork and collective problem-solving, flat hierarchies in organizations and a society that encourages participation, a culture that values consensus and cooperation over individual competition, and social safety nets that provide security, allowing for risk-taking. This creates an environment where it is safe to engage in innovation and seize the opportunities life offers.

Collaboration is the power to change the world

The strong collaboration between the public and private sectors forms the backbone of Finland’s innovation economy. Industries, research institutes, universities, and the government together have a unique ability to deliver disruptive technologies and innovative design. Finland consistently ranks among the world’s leading countries in education, innovation, digitalization, sustainability, and good governance, making it one of the world’s hotspots for R&D. To give it a further boost, Finland aims to increase research and development expenditure to 4% of GDP by 2030.

Finland boasts a thriving startup scene with an estimated number of 3 800 startups. The Finnish startup ecosystem has always been about pooling resources, lending a hand, and helping one another. When one business is successful, it benefits the whole network – a rising tide lifts all boats. Finland's startup ecosystem has given birth to more than 10 unicorns, many of which stem from academia.

An example of open-minded cooperation in building R&D is the Leading Companies Program. Here, Business Finland challenges global companies to undertake ambitious research efforts while encouraging companies of different sizes and other players to work together, sharing knowledge and resources, aiming to achieve breakthroughs that solve major global challenges – and do business. So far, the scheme has supported 400 companies in Finland and 400 research projects by universities and other research institutes. The Leading Companies Program is open to international companies that have a subsidiary in Finland.

Finland invites you to innovate in the state of happiness

Collaboration with Finns is defined by sisu – a uniquely Finnish concept of integrity-driven determination and courage under pressure. It means acting with deep resolve while upholding a strong commitment to mutual respect among collaborators. Promises are kept, and things are done well even when no one is watching.

Johanna Jäkälä, Executive Director, Finland Promotion Services from Business Finland says:

“Collaboration, along with sisu, is really in the DNA of Finland. No one creates change alone, and that is why we are committed to bringing people and businesses together to team up, make unexpected connections, solve problems together, and create an impact.”

For the 8th year in a row, Finland has been named the happiest country in the world by the annual United Nations World Happiness Report*, holding the top title since 2018.

ABOUT

Business Finland is the Finnish government organization for innovation funding and trade, travel, and investment promotion. Business Finland’s over 760 experts work in over 40 offices globally and in 16 regional offices around Finland. Business Finland is part of the Team Finland network. www.businessfinland.com

Invest in Finland helps foreign companies identify business opportunities in Finland, produces information on Finland as an investment destination, and enhances and coordinates national efforts to attract investment by actively networking with regional and international entities. Invest in Finland also collects and updates information about foreign-owned companies in Finland. Invest in Finland is part of Business Finland.

Work in Finland attracts talents and startup founders to Finland and help companies to recruit international professionals. www.workinfinland.com is a national website for talent attraction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319812998/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye